GB Sciences Inc
OTC:GBLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GB Sciences Inc
OTC:GBLX
|
US |
|
E
|
Etteplan Oyj
OMXH:ETTE
|
FI |
|
Perimeter Solutions SA
NYSE:PRM
|
LU |
|
PepGen Inc
NASDAQ:PEPG
|
US |
|
R
|
Resbud SE
WSE:RES
|
EE |
|
BlueScope Steel Ltd
ASX:BSL
|
AU |
|
T
|
Tansun Technology Co Ltd
SZSE:300872
|
CN |
|
State Trading Corporation of India Ltd
NSE:STCINDIA
|
IN |
|
D
|
Dream Security Co Ltd
KOSDAQ:203650
|
KR |
|
Trada Alam Minera Tbk PT
IDX:TRAM
|
ID |
|
T
|
Tofflon Science and Technology Group Co Ltd
SZSE:300171
|
CN |
|
Accuracy Shipping Ltd
NSE:ACCURACY
|
IN |
|
Petronas Gas Bhd
KLSE:PETGAS
|
MY |
|
Quanterix Corp
NASDAQ:QTRX
|
US |
|
China Taiping Insurance Holdings Co Ltd
HKEX:966
|
HK |
|
T
|
Taaleri Oyj
OMXH:TAALA
|
FI |
|
O
|
OrderYOYO A/S
CSE:YOYO
|
DK |
|
S
|
SosTravel.com SpA
MIL:SOS
|
IT |
|
O
|
Oriola Oyj
OMXH:OKDBV
|
FI |
|
New Horizon Health Ltd
HKEX:6606
|
CN |
|
PTC India Financial Services Ltd
NSE:PFS
|
IN |
|
R
|
Rhinebeck Bancorp Inc
NASDAQ:RBKB
|
US |
|
F
|
Fom Technologies A/S
CSE:FOM
|
DK |
|
V
|
Vistareit Inc
XPHS:VREIT
|
PH |
GB Sciences Inc
GB Sciences, Inc. is a phytomedical research and biopharmaceutical drug development company, which focus on treating diseases with cannabinoid medicines. The company is headquartered in Las Vegas, Nevada and currently employs 16 full-time employees. The company went IPO on 2003-12-22. The firm is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. The company offers artificial intelligence (AI) accelerated drug discovery platform, PhAROS, Phytomedical Analytics for Research Optimization at Scale. The PhAROS platform is a science gateway and virtual research environment for drug discovery. Through its subsidiary, GBS Global Biopharma, Inc., the company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. The firm's list of subsidiaries includes GBS Global Biopharma, Inc., ECRX, Inc., The PhAROS Institute, LLC, GB Sciences Texas, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC and GB Sciences Nopah, LLC.
GB Sciences, Inc. is a phytomedical research and biopharmaceutical drug development company, which focus on treating diseases with cannabinoid medicines. The company is headquartered in Las Vegas, Nevada and currently employs 16 full-time employees. The company went IPO on 2003-12-22. The firm is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. The company offers artificial intelligence (AI) accelerated drug discovery platform, PhAROS, Phytomedical Analytics for Research Optimization at Scale. The PhAROS platform is a science gateway and virtual research environment for drug discovery. Through its subsidiary, GBS Global Biopharma, Inc., the company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. The firm's list of subsidiaries includes GBS Global Biopharma, Inc., ECRX, Inc., The PhAROS Institute, LLC, GB Sciences Texas, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC and GB Sciences Nopah, LLC.
